CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.
about
Immunobiology of hepatocarcinogenesis: Ways to go or almost there?Cancer immunotherapy: the beginning of the end of cancer?Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint RegulatorsTim-3 and Tim-4 as the potential targets for antitumor therapyMolecular mechanisms of T cell co-stimulation and co-inhibitionImpaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?Alginic acid-coated chitosan nanoparticles loaded with legumain DNA vaccine: effect against breast cancer in micePhenotypic T cell exhaustion in a murine model of bacterial infection in the setting of pre-existing malignancyThe blockade of immune checkpoints in cancer immunotherapyImmune checkpoint therapy for pancreatic cancerRole of TIM-3 in ovarian cancer.T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrinsTumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells.Minimal changes in the systemic immune response after nephrectomy of localized renal masses.PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients.TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustionTim-3 expression defines regulatory T cells in human tumors.Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironmentNew insights into cancer immunoediting and its three component phases--elimination, equilibrium and escapeAn exhaustion-like phenotype constrains the activity of CD4+ T cells specific for a self and melanoma antigen.Murine lung cancer induces generalized T-cell exhaustion.PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid CancerInhibitory Receptors Beyond T Cell Exhaustion.Consensus nomenclature for CD8(+) T cell phenotypes in cancerRecent developments on immunotherapy for brain cancer.Inhibitory receptors as targets for cancer immunotherapyBTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties.Elevated Expression of CD160 and 2B4 Defines a Cytolytic HIV-Specific CD8+ T-Cell Population in Elite Controllers.Serum-based tracking of de novo initiated liver cancer progression reveals early immunoregulation and response to therapy.PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "Exercising" an alternative viewpointCirculating and tumor-infiltrating Tim-3 in patients with colorectal cancer.T-cell exhaustion in the tumor microenvironment.Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cbl-b in patients with gallbladder cancer.Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor.Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy.Lymphotoxin network pathways shape the tumor microenvironmentCheckpoint modulation in melanoma: an update on ipilimumab and future directions.
P2860
Q26738293-2F2E18A5-8AD3-4052-9E81-C6B81FA93206Q26752277-63FD4CD5-98EC-4060-B543-411B00AD9546Q26782799-B00F2976-8F88-49EC-A819-E46BE190D94AQ26799502-25917B3E-5550-452A-9048-1AAA6A9C1A01Q26864888-18D58947-9BBE-4DBE-A285-8D586883229BQ27003955-D262E348-9A91-45B9-A78C-85CC1CFB2C16Q27331013-6005A3D3-CB07-4A9F-BCB9-753604439ADCQ27346770-1D0BD9ED-3EEA-4741-9541-E53F514E53EAQ27860852-B4F8FB1A-BF65-450D-A077-5F68919A3A1BQ28078390-1C5F64C0-01C8-4704-8049-3EC0AF4479AEQ30235023-6E7504EF-0E23-4484-8718-6DD7BB3873CDQ30408331-66EBDA55-EB35-45CB-9C06-A4CE137AA3AFQ30916013-9D14D75C-1295-4299-9C35-61F6E11AAD59Q33768093-F7A3D021-8518-4571-BF8D-C6862CB1EAA2Q34014728-A5D196C0-E65D-4127-9A0B-2BA03409FAE5Q34283708-68E4172E-2960-4B41-8624-7256238E9C9CQ34471375-E75CBDB5-1F42-4C38-B397-71CE69B7AE42Q34626229-A1D98416-A8F5-4402-AAE2-10BE855D360EQ34634058-558F1451-B093-46B4-B7F5-EBEEAD62DD07Q34658452-9AC1F3F4-6C6C-46B9-9422-7C14E0B1B3C1Q35044301-0C6970E2-CA1B-440D-AE51-7420A6B54750Q35300077-99B2B6D2-F3B6-4D86-9773-434F680DCE00Q35431621-065E4294-281B-4512-903C-47D9375AD8F3Q35562860-B003E245-132A-471D-90C1-20A2F907B8D0Q35688947-2D02900B-D77A-46B5-B34A-A4110A044220Q35783318-A3D1A949-7112-40C3-9F52-0EC85328871BQ35798822-948A94B1-7EAF-4EEE-88FC-36865427D2EEQ35992355-61F7302E-CC81-46D9-8468-3C9667934396Q35995373-0919ED9E-DB58-4CCE-BDE9-3EFDBC15D8C7Q36060241-C4685BAC-A5F9-4D4B-B4E7-D2A7DBD350E9Q36148988-977571A8-799E-4C83-83EA-0F11E966EEBBQ36190850-1C23EEBF-879E-4BA6-8A19-A8658509E0F5Q36194853-7BF972A9-4E78-4374-8818-4F859FF4FC40Q36299762-1053D491-2E3D-4E9D-9BAD-01D1B0FD8417Q36347369-BE16ACAB-4B8E-41ED-BAE3-20D794D74B3EQ36467408-FBCDF33C-0812-499F-B234-CE4CF2ACDE24Q36711034-9AFD5A10-E8A8-4193-AB45-53EE0FB4E637Q36791129-530862E3-4C2A-4E3C-8569-5C69BF205D6AQ36823937-1220E8A1-BA46-4B1B-9B4F-0C5BA6E112C4Q37237761-F02917BD-B4B1-4534-ADEE-C11E82530345
P2860
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
CD8(+) T cells specific for tu ...... itory receptors BTLA and PD-1.
@ast
CD8(+) T cells specific for tu ...... itory receptors BTLA and PD-1.
@en
type
label
CD8(+) T cells specific for tu ...... itory receptors BTLA and PD-1.
@ast
CD8(+) T cells specific for tu ...... itory receptors BTLA and PD-1.
@en
prefLabel
CD8(+) T cells specific for tu ...... itory receptors BTLA and PD-1.
@ast
CD8(+) T cells specific for tu ...... itory receptors BTLA and PD-1.
@en
P2093
P2860
P1433
P1476
CD8(+) T cells specific for tu ...... itory receptors BTLA and PD-1.
@en
P2093
Cindy Sander
Daniel Olive
Hassane M Zarour
Immanuel F Luescher
John M Kirkwood
Julien Fourcade
Ornella Pagliano
Philippe Guillaume
Vijay Kuchroo
Zhaojun Sun
P2860
P304
P356
10.1158/0008-5472.CAN-11-2637
P407
P577
2011-12-28T00:00:00Z